CHRNA2 GENETIC MARKERS ASSOCIATED WITH GALANTAMINE RESPONSE
摘要
Haplotypes in the CHRNA2 gene associated with cognitive response to galantamine treatment are disclosed. Compositions and methods for detecting and using these CHRNA2 hyplotypes in a variety of clinical applications are disclosed. Such applications include articles of a manufacture comprising galantamine or derivatives thereof that are approved for treating patients having one of these CHRNA2 haplotypes, methods and kits for predicting the response of an individual to galantamine based upon his/her haplotype profile, and methods for treating Alzheimer's patients based upon their haplotype profile.
申请公布号
WO2005021796(A2)
申请公布日期
2005.03.10
申请号
WO2004US22457
申请日期
2004.07.12
申请人
GENAISSANCE PHARMACEUTICALS, INC.
发明人
AERSSENS, JEROEN;ATHANASIOU, MARIA;BRAIN, CARLOS;COHEN, NADINE;DAIN, BRADLEY;DENTON, R., REX;JUDSON, RICHARD, S.;OZDEMIR, VURAL;REED, CAROL, R.